Skip to main content

IBA推出多功能高能新型回旋加速器

-

Wednesday, June 23, 2021 - 8:26

<p><span><span><span><span><span><strong><span><span><span>IBA</span></span></span></strong><strong><span lang="FR-BE"><span><span>推出多功能高能新型回旋加速器</span></span></span></strong></span></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><span lang="ZH-CN"><span><span>今年</span></span></span><span><span><span>6</span></span></span><span lang="ZH-CN"><span><span>月,</span></span></span><span><span><span>IBA</span></span></span><span lang="ZH-CN"><span><span>发布了<strong>全新</strong></span></span></span><strong><span><span><span>Cyclone</span></span></span></strong><strong><span><span><span><sup>® </sup></span></span></span></strong><strong><span><span><span>IKON</span></span></span></strong><strong><span lang="ZH-CN"><span><span>回旋加速器</span></span></span></strong><span lang="ZH-CN"><span><span>。这款全新多功能高能回旋加速器汇集了</span></span></span><span><span><span>35</span></span></span><span lang="ZH-CN"><span><span>年来的经验与创新,兼顾提高放射性诊疗药物生产效率与减少放药中心占用面积的特点。</span></span></span><span><span><span>Cyclone® IKON</span></span></span><span lang="ZH-CN"><span><span>为</span></span></span><span><span><span>PET</span></span></span><span lang="ZH-CN"><span><span>和</span></span></span><span><span><span>SPECT</span></span></span><span lang="ZH-CN"><span><span>核素提供了更大能量范围从</span></span></span><span><span><span>13 MeV</span></span></span><span lang="ZH-CN"><span><span>到</span></span></span><span><span><span>30 </span></span></span><span><span><span>MeV</span></span></span><span lang="ZH-CN"><span><span>可调</span></span></span><span lang="ZH-CN"><span><span>,并在此次网络发布会现场活动中得到展示。</span></span></span></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><span lang="ZH-CN"><span><span>点击下面的视频观看重播:</span></span></span></span></span></span></span></p> <p><strong><em><span lang="ZH-CN"><span><span><a href="https://v.youku.com/v_show/id_XNTE3Mjc0MTA1Ng==.html?spm=a2h0c.8166622.PhoneSokuUgc_1.dtitle">https://v.youku.com/v_show/id_XNTE3Mjc0MTA1Ng==.html?spm=a2h0c.8166622.PhoneSokuUgc_1.dtitle</a></span></span></span></em></strong></p> Read full press release  
Share

news.more_news_title

IBA et SCK CEN lancent Pantera

IBA and SCK CEN launch Pantera, a joint-venture to produce actinium-225

Louvain-La-Neuve, Belgium, 22 September 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre SCK CEN today announced the name of their joint-venture: Pantera SA/NV, which they believe will bring new hope for cancer patients. As indicated in the announcement of the R&amp;D strategic partnership, this new company will aim to secure the large-scale production of actinium-225 (225Ac), one of the most promising alpha-emitting radioisotopes to fight cancers. By working towards this large-scale production, Pantera’s ultimate goal is to improve the accessibility of a future innovative cancer therapy based on 225Ac. &nbsp; The complementarity of IBA and SCK CEN’s expertise has been demonstrated by the extensive and comprehensive R&amp;D work that has been conducted during the last year as they work towards being able to produce large volumes of 225Ac. Pantera is now completing the technical feasibility studies before working on the final design and construction of its first facility in Mol, Belgium. Groundbreaking is expected to take place in 2024, with production starting in 2027. &nbsp; Sven Van den Berghe, former Director of the Nuclear Materials Science Institute at SCK CEN, has been appointed as Chief Executive Officer, and Samy Bertrand, former technical leader for theranostics applications at IBA, takes the position of Chief Technical Officer. &nbsp; Bruno Scutnaire, President of IBA RadioPharma Solutions and Chairman of the Board of Directors of Pantera, said: “Actinium-225 offers great promise for the treatment of a large variety of cancers, but only very little of the material is available worldwide today.&nbsp; Once cancer treatments based on 225Ac receive approval, Pantera will focus on enabling access to a dependable supply of this promising isotope.” &nbsp; Peter Baeten, Deputy Director-General of SCK CEN and Board member of Pantera, commented: “Launching Pantera was a logical choice for SCK CEN and IBA, allowing the joint-venture to leverage the innovative capabilities of both organizations, whilst utilizing the speed of an autonomous startup necessary in this fast-evolving field.” &nbsp; Sven Van den Berghe, appointed Chief Executive Officer of Pantera, added: “I am excited about the opportunity to help advance the mission of Pantera to bring a new hope for cancer patients by enabling the widespread use of radioisotopes, such as actinium-225, as a basis for promising new radiopharmaceuticals. Pantera offers ’A better fight for life’, potentially bringing an effective and efficient treatment option while maximizing the quality of life of the patients, with the possibility to expand the production to other isotopes in the future.” &nbsp; Actinium-225 possesses the resounding potential to treat cancers more effectively. Initial results show that the theranostic radioisotope completely eliminates cancer cells, rather than just inhibiting tumour growth. The risk of recurrence also appears to decrease. To date, extensive research and numerous studies are underway which aim to tackle both high prevalence cancers including prostate, lung, colon, breast, pancreatic, blood (leukemia and other rare forms) and kidney cancers, but also rarer forms of cancer like glioblastoma, the deadliest form of a very invasive brain cancer. &nbsp;
查看更多
IBA和SCK CEN成立合资公司Pantera 合作生产锕-225

IBA和SCK CEN成立合资公司Pantera 合作生产锕-225

比利时新鲁汶2022年9月22日 - IBA(Ion Beam Applications S.A.,泛欧交易所上市公司),粒子加速器技术的世界领先者之一,与比利时核能研究中心SCK CEN于今日宣布双方合资公司名称为:Pantera SA/NV,双方相信该公司的成立将为癌症患者带来新的希望。正如研发战略合作公告中所示,这家新公司的目标是确保锕-225(Ac-225)的大规模生产,锕-225是最有希望用于对抗癌症的α放射性同位素之一。通过实现这种同位素的大规模生产,Pantera的最终目标在于提高基于锕-225未来创新癌症疗法的可及性。 &nbsp; IBA和SCK CEN去年进行了广泛而全面的研发合作,致力于大批量生产锕-225,双方在各自专业领域上的互补性在合作中得以体现。Pantera目前正在完成技术可行性研究,之后将开始对其位于比利时莫尔的第一家工厂进行最终设计和建造。预计将于2024年动工,并于2027年投入生产。 SCK CEN核能研究中心前院长Seven Van den Berghe已被任命为首席执行官,而IBA治疗诊断学应用前技术负责人Samy Bertrand将担任首席技术官。 IBA放射制药解决方案总裁兼Pantera董事会主席Bruno Scutnaire表示:“锕-225为多种癌症的治疗提供了巨大希望,但目前全球范围内可用之材甚少。一旦基于锕-225的癌症治疗获得批准,Pantera将专注于让这种具有前景的同位素实现可靠供应。” SCK CEN副总干事兼 Pantera 董事会成员 Peter Baeten 评论说:“成立Pantera 是 SCK CEN 和 IBA 的合理选择,它使得合资企业能够利用双方的创新能力,同时在这个快速发展的领域中,充分利用必要的自主创业速度。” 被任命为 Pantera 首席执行官的 Sven Van den Berghe 补充说:“我为能获得这个帮助 Pantera 推进使命前行,通过广泛使用作为新兴放射性药物基础的放射性同位素如锕-225,为癌症患者带来新希望的机会感到兴奋。Pantera 提供‘更好地为生存而战’的机会,有希望带来有效和高效的治疗选择,同时最大限度地提高患者的生活质量,并有可能在未来将生产扩展到其他同位素的生产上。” 锕-225拥有更加有效治疗癌症的巨大潜力。初步结果表明,用于治疗的放射性同位素可以完全消除癌细胞,而不仅仅是抑制肿瘤生长。复发的风险似乎也降低了。到目前为止,旨在应对高发病率癌症及罕见癌症的广泛调查和大量研究正在进行中,高发病率癌症包括前列腺癌、肺癌、结肠癌、乳腺癌、胰腺癌、血癌(白血病和其他罕见病)和肾癌在内的高发病率癌症,罕见的癌症,如胶质母细胞瘤,这是一种最致命的侵袭性脑癌。 ***结束*** 关于IBA IBA(Ion Beam Applications S.A.)是粒子加速器技术的世界领先者。该公司是质子治疗领域设备和服务的领先供应商之一,被认为是当今更先进的放射治疗形式。IBA 还是工业灭菌、放射性药物和剂量学领域的领先企业之一。该公司总部位于比利时新鲁汶,在全球拥有约1,600名员工。IBA是一家通过共益企业 (B Corp)认证的公司,符合经验证的社会和环境绩效的最高标准。 IBA在泛欧证券交易所(EURONEXT)上市(IBA:路透社IBAB.BR 和彭博社 IBAB.BB)。 更多信息,请访问:www.iba-worldwide.com &nbsp; 关于SCK CEN CK CEN是比利时最大的研究中心之一。其拥有 850 多名员工,每天都致力于核能的开发和和平应用。SCK CEN的研究活动涉及三个部分:核设施的安全、核医学的发展以及保护人员和环境免受电离辐射。SCK CEN在全球得到认可,并通过众多出版物和培训课程分享其知识,以不断保持这一个卓越领域里的的人才储备。 更多信息,请访问:www.sckcen.be
查看更多
Jiming Cai, General Manager of CNRT; Chen Li,  IBA Radio Pharma Solutions Sales VP China

CNRT and IBA sign collaboration agreement to install a Cyclone® IKON in China

The Cyclone® IKON is IBA’s new high energy and high-capacity cyclotron which offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV Louvain-La-Neuve, Belgium, August 30, 2022 –IBA(Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, announced it has signed a collaboration agreement with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone® IKON in Chengdu, Sichuan Province, China. CNRT is a Chinese manufacturer and provider of medical isotopes used for oncology diagnosis and therapy. The typical end-user price for a Cyclone® IKON solution is between EUR 15 and 20 million. The Cyclone® IKON will be used for the production of novel isotopes for use in theranostics and targeted therapies, particularly for Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123 and other radioisotopes such as Copper-64. These enable the administration of radiation directly to the targeted cells, with minimal toxic side effects to surrounding healthy cells, unlike traditional modalities. Jiming Cai, General Manager of CNRT, commented: “We are pleased to be working with IBA to develop a stable and independent supply of commonly used medical isotopes. This will be the first Cyclone® IKON cyclotron system to be installed by IBA in China for the production of multiple radioisotopes, and is expected to be fully operational by 2025. In due course CNRT will be able to provide high-quality and efficient medical isotopes to our clients.” &nbsp; Bruno Scutnaire, President of IBA RadioPharma Solutions, added: “There are a growing number of clinical trials and an increase in new radiotherapeutic molecule developments, with many companies recognizing the great potential of theranostics. Since its launch in 2020, this is the fourth Cyclone® IKON unit sold globally and we look forward to working with CNRT over the coming months and years.” &nbsp; About CNRT Chengdu New Radiomedicine Technology Co., Ltd. was established in the year 2016. It is a high-tech enterprise integrating Research and development of radiopharmaceuticals, innovation and industrialization, engaged in research, production and sales of medical isotopes, carry out demonstration research on the diagnosis and treatment of a variety of malignant tumor diseases, provide nuclear medicine technical services and scientific and technological consulting, etc. The company has built up an advanced radiopharmaceutical testing and research platform, an advanced radioactive pharmacology research platform, and an advanced radiopharmaceutical industrialization innovation platform. CNRT will ensure continuously provide high-quality, High efficiency and affordable radioactive diagnosis and treatment drugs for the patients, provide high-quality medical isotope nuclide products for the radiopharmaceutical industry, through technology, concept and products innovation. About IBA IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com &nbsp; CONTACTS Soumya Chandramouli Chief Financial Officer +32 10 475 890 Investorrelations@iba-group.com &nbsp; Olivier Lechien Corporate Communication Director +32 10 475 890 communication@iba-group.com &nbsp; Consilium Strategic Communications Amber Fennell, Angela Gray, Lucy Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com
查看更多
Jiming Cai, General Manager of CNRT; Chen Li,  IBA Radio Pharma Solutions Sales VP China

纽瑞特与IBA签署合作协议在中国安装Cyclone® IKON

Cyclone® IKON是IBA全新高能高容量且可提供最大13-30MeV能量范围的 PET和SPECT回旋加速器 比利时新鲁汶2022年08月30日-IBA (Ion Beam Applications S.A., 泛欧交易所上市公司), 世界领先的粒子加速器技术和放射药物解决方案供应商,宣布已与成都纽瑞特医疗科技股份有限公司(以下简称CNRT)签署合作协议,在中国四川省成都市安装Cyclone®IKON。CNRT是用于肿瘤诊断和治疗的医用同位素的中国制造商和供应商。Cyclone® IKON解决方案的典型最终用户价格在1500-2000万欧元之间。 Cyclone® IKON将用于生产诊断治疗和靶向治疗的新型同位素的生产中,特别是锗-68(用于68Ge/68Ga发生器)、碘-123和其它放射性同位素,如铜-64。与传统方式不同,这些元素得以让辐射直接作用于靶向细胞,对周围健康细胞的毒副作用最小。 &nbsp; CNRT总经理蔡继鸣表示:“我们很高兴与IBA合作,开发稳定独立的常用医用同位素供应链,这将是IBA在中国安装的首套用于生产多种放射性同位素的Cyclone® IKON回旋加速器系统,该项目预计将于2025全面投入运营。届时,CNRT将能够为我们的客户提供高质和高效的医用同位素。” &nbsp; Bruno Scutnaire,IBA 放射药物解决方案总裁补充说:随着许多公司认识到诊疗一体化的巨大潜力,临床试验和新的放射治疗分子开发的数量逐渐增加。自2020年推出以来,这是全球销售的第四台Cyclone® IKON设备,我们非常期待在未来的几个月份和年度里与CNRT的合作。” &nbsp; 成都纽瑞特医疗科技股份有限公司于成立于2016年,是一家从事医用同位素和放射性诊疗药物研究、生产、销售,开展多种恶性肿瘤疾病的诊断与治疗示范研究,提供核医学技术服务和科技咨询等集放射性药物研发、创新与产业化的高新技术企业。公司已建成先进的放射性药物检验研究平台、先进的放射性药理研究平台、先进的放射性药物产业化创新平台。纽瑞特公司将始终致力于通过技术、理念和产品的创新,为广大患者提供优质、优效、经济的放射性诊疗药物,为放射性药物行业提供高品质的医用同位素核素产品。 IBA(Ion Beam Applications S.A.)是粒子加速器技术的世界领先者之一。该公司是质子治疗领域设备和服务的领先供应商之一,被认为是当今更先进的放射治疗形式。IBA 还是工业灭菌、放射性药物和剂量学领域的领先企业之一。该公司总部位于比利时新鲁汶,在全球拥有约1,600名员工。IBA是一家通过共益企业 (B Corp)认证的公司,符合经验证的社会和环境绩效的最高标准。 IBA在泛欧证券交易所(EURONEXT)上市(IBA:路透社IBAB.BR 和彭博社 IBAB.BB)。 更多信息,请访问:www.iba-worldwide.com 联系方式 Soumya Chandramouli Chief Financial Officer 首席财务官 +32 10 475 890 Investorrelations@iba-group.com &nbsp; Olivier Lechien Corporate Communication Director 企业传播总监 +32 10 475 890 communication@iba-group.com &nbsp; Consilium Strategic Communications Amber Fennell, Angela Gray, Lucy Featherstone 咨询战略沟通 +44 (0) 20 3709 5700 IBA@consilium-comms.com
查看更多